1-Methylnicotinamide Chloride Powder

In cells, nicotinamide N-methyltransferase (NNMT) transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide, yielding 1-MNA and S-adenosylhomocysteine (SAH). This reaction connects vitamin B3 metabolism with cellular methyl-group use. The resulting 1-MNA can be further oxidized to the pyridone metabolites 2PY and 4PY, which, along with 1-MNA, can be measured in biological samples.

A useful experimental design measures nicotinamide, 1-MNA, SAM, SAH, and pyridone metabolites together. An increase in 1-MNA alone may suggest a change in this pathway, but it cannot uniquely identify the cause: precursor availability, NNMT activity, downstream oxidation, and elimination can each affect the observed concentration. This is an inference from the pathway and its multiple measured components.

• Induction of Endogenous Prostacyclin

Molecular Target: 1-MNA significantly upregulates the expression and enzymatic activity of Cyclooxygenase-2 (COX-2) and Prostacyclin Synthase (PGIS) in vascular endothelial cells.

Physiological Effect: Specifically stimulates endothelial cells to release Prostacyclin (PGI₂), exerting potent effects in vasodilation, inhibition of platelet aggregation, and antithrombosis.

• Inhibition of Endothelial Pro-inflammatory Factors & Adhesion Molecules

Downregulates the expression of ICAM-1, VCAM-1, and E-selectin, preventing leukocyte adhesion and infiltration into the vascular endothelium, thereby mitigating vascular endothelial inflammatory injury.

• NNMT/1-MNA Metabolic Axis & NAD+ Homeostasis Regulation

As a key enzymatic product of Nicotinamide N-Methyltransferase (NNMT), 1-MNA regulates the cellular S-adenosylmethionine to S-adenosylhomocysteine (SAM/SAH) ratio (methyl donor balance) and indirectly impacts the NAD+ salvage pathway.

Urinary 1-MNA has been investigated as a marker of niacin-related metabolism. In cohort research, investigators have measured 24-hour urinary excretion with LC–MS/MS and considered its relationship to nutritional status and health outcomes. Such associations need careful interpretation: urine collection, dietary intake, renal function, and the metabolism of 1-MNA into pyridones can all influence the result.

For studies comparing groups, a single spot-urine concentration is therefore a different measurement from total 24-hour excretion. The sampling strategy and normalization method should be specified before interpreting a difference as altered NNMT activity.

Because 1-MNA is an endogenous organic cation, it has been studied in relation to renal OCT2 and MATE transporters and as a possible indicator of transporter-mediated drug interactions. Plasma and urine assays provide complementary information about its handling.

Its value as a specific transporter biomarker remains an active research question. A 2025 experimental assessment highlighted limitations in treating 1-MNA as a sensitive, selective readout for OCT2 and identified transport by OCT1 as an additional consideration. Studies should therefore avoid attributing a change in 1-MNA solely to one transporter without supporting controls or complementary markers.

Experimental work has examined whether 1-MNA affects endothelial responses, prostacyclin signaling, and platelet-dependent thrombosis. In an animal study, an antithrombotic effect was linked to a mechanism involving cyclooxygenase-2 and prostacyclin; separate cell research has examined endothelial responses under inflammatory conditions. These findings define testable mechanisms, but their effects depend on the model and exposure studied.

For cell experiments, useful controls include vehicle-treated cells, concentration and exposure-time series, cell viability, and direct measurements of the proposed pathway. An observed change in an inflammatory marker alone should not be described as proof of a broad clinical vascular benefit.

The role of 1-MNA can vary with biological context. In research on human ovarian cancer, investigators identified 1-MNA as an immune-regulatory metabolite associated with NNMT activity in the tumor environment. This is a different question from whether externally supplied 1-MNA produces a beneficial response in a vascular model.

This distinction is important for product descriptions: results from one tissue, cell type, or disease model should not be generalized to all inflammatory or metabolic settings. Studies using the powder should specify whether they are measuring endogenously produced 1-MNA or experimentally adding the chloride salt.

Vascular Protection & Cardiovascular Health

Approved as a Novel Food ingredient in Europe (EFSA/EMA evaluated), 1-MNA is widely utilized in formulations aimed at improving vascular health, microcirculation, and endothelial integrity.

Dermatological & Anti-inflammatory Topical Uses

Exhibits excellent transdermal permeability; topical application inhibits Cutibacterium acnes-induced skin inflammation, making it suitable for anti-acne, anti-erythema (rosacea), and skin barrier repair formulations.

Neuroprotection & CNS Injury Mitigation

Reduces microglial hyperactivation, demonstrating neuroprotective efficacy and microvascular circulation improvement in ischemic stroke and reperfusion injury models.